Although this study lacks validation in an independent cohort, HMGB1 and the HMGB1/sRAGE ratio clearly seem to be promising and easily accessible biomarkers for the detection of ovarian cancer and possibly even for benign ovarian diseases. Here, HMGB1 is linked to ovarian cancer.